Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer
Metrics: PDF 1003 views | HTML 1298 views | ?
DeSheng Xiao1,2, Can Lu1,2, Wei Zhu1,2, QiuYan He1,2, Yong Li1,2, ChunYan Fu1,2, JianHua Zhou1,2, Shuang Liu6, YongGuang Tao3,4,5,6
1Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078 China
2Department of Pathology, School of Basic Medicine, Central South University, Changsha, Hunan 410078 China
3Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, 410078 China
4Key Laboratory of Carcinogenesis and Cancer Invasion (Central South University), Ministry of Education, Hunan, 410078 China
5Key Laboratory of Carcinogenesis (Central South University), Ministry of Health, Hunan, 410078 China
6Center for Medicine Research, Xiangya Hospital, Central South University, Changsha, Hunan, 410008 China
YongGuang Tao, email: email@example.com
Keywords: EGFR, EML4-ALK, small biopsy specimens, surgical specimens, non-small-cell lung carcinoma
Received: March 29, 2016 Accepted: May 29, 2016 Published: June 14, 2016
Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion genes represent novel oncogenes that are associated with non–small-cell lung cancers (NSCLC). The feasibility of detecting EGFR mutations and ALK fusion genes in small biopsy specimens or surgical specimens was determined. Of the 721 NSCLC patients, a total of 305 cases were positive for EGFR mutations (42.3%). The rate of EGFR mutations in women was significantly higher than that in men. Histologically, the EGFR mutation rate in adenocarcinomas was significantly higher than that in squamous cell carcinomas. No difference in the EGFR mutation rate was observed between surgical specimens (42.1%) and small biopsy specimens (42.4%), which indicated that the EGFR mutation ratios in surgical specimens and small biopsy specimens were not different. In 385 NSCLC patients, 26 cases were positive for EML4-ALK (6.8%). However, 11.7% of the surgical specimens were EML4-ALK-positive, whereas the positive proportion in the small biopsy specimens was only 4.7%, which indicated that EML4-ALK-positive rate in the surgical specimens was significantly higher than that in the small biopsy specimens. Detection of EGFR gene mutations was feasible in small biopsy specimens, and screening for EML4-ALK expression in small biopsy specimens can be used to guide clinical treatments.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.